Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Rusan Apomorphine Hydrochloride

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Apomorphine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 18,664Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Supernus Announces Second Quarter 2024 Financial Results
    Supernus Announces Second Quarter 2024 Financial Results

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925489/19871/en/Supernus-Announces-Second-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    Supernus Announces First Quarter 2024 Financial Results
    Supernus Announces First Quarter 2024 Financial Results

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2878228/19871/en/Supernus-Announces-First-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    FTC says patent battle over Parkinson's drug have 'significant implications'
    FTC says patent battle over Parkinson's drug have 'significant implications'

    21 Mar 2023

    // Nicole DeFeudis ENDPTS

    https://endpts.com/ftc-says-patent-battle-over-parkinsons-drug-could-have-significant-implications-for-patients/

    Nicole DeFeudis ENDPTS
    21 Mar 2023
    Share Share
    Enforcement Report - Week of February 1, 2023
    Enforcement Report - Week of February 1, 2023

    01 Feb 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11202310416

    FDA
    01 Feb 2023
    Share Share
    FDA rejects Supernus’ drug infusion device for Parkinson’s
    FDA rejects Supernus’ drug infusion device for Parkinson’s

    11 Oct 2022

    // Delilah Alvarado BIOPHARMADIVE

    https://www.biopharmadive.com/news/supernus-fda-rejection-parkinsons-crl/633685/

    Delilah Alvarado BIOPHARMADIVE
    11 Oct 2022
    Share Share
    Celera's apomorphine therapy device for Parkinson’s set as alternative to DBS
    Celera's apomorphine therapy device for Parkinson’s set as alternative to DBS

    09 Mar 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=146297&sid=2

    PHARMABIZ
    09 Mar 2022
    Share Share